Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
Round 1
Reviewer 1 Report
Look at the attachement
Comments for author File: Comments.pdf
Author Response
Please see the attachment
Author Response File: Author Response.pdf
Reviewer 2 Report
This is an interesting review article on a clinically important issue. As a valid biomarker is not available, new efforts are needed to diagnose NASH with some degree of certainty. Under these perspectives, some more aspects should be discussed.
My points are:
Fig 1 is interesting and should benefit from adding references for the items. The figure could be moved more at the end, avoiding new order of the reference list. Please discuss CYP 2E1 relationship of NASH to ASH, referencing for instance: Biomedicines 2018: 6, 106. Also, are in NASH CYP 2E1 exosomes present in the blood as in ALD? To make the paper more interesting, you may discuss the relationship between NASH and adipose tissue. What about the inztestinal microbiome?Author Response
Please see the attachment
Author Response File: Author Response.pdf
Reviewer 3 Report
This is a very well written and comprehensive review addressing many aspects of NAFLD; maybe the tittle should be more general, not only biomarkers for detection of NAFLD.
I have a few comments that the authors may want to address to improve the quality of the manuscript.
-Introduction line 2: non-insulin dependent diabetes, this classification is not correct, instead of this use type 2 diabetes.
-Line 248-249- might be not exclusively related to NAFLD, include not in the phrase.
-Line 282- use well studied instead of well-study
- Line 283-Confer reference 66 is not approbatively cited in the text
Line 294, 295,296- include references for this phrase
Line 31,317,318- include references for the biomarkers cited.
Line 415,416,417- I would be more cautious, the reference cited by the authors is of a metanalysis that included only retrospective studies, the method had high accuracy for diagnosis of significant or advanced fibrosis and cirrhosis, but it was not evaluated if it was appropriate to detect progression of fibrosis. “Therefore, this image modality is highly suitable to detect progression and treatment response in patients with chronic liver disease.” For example :may be highly suitable…..
Author Response
Please see the attachment
Author Response File: Author Response.pdf
Round 2
Reviewer 1 Report
Nice work